oligopeptide histrelin http://purl.bioontology.org/ontology/MESH/C029256 http://purl.bioontology.org/ontology/SNOMEDCT/109049002 http://purl.obolibrary.org/obo/CHEBI_5739 http://purl.obolibrary.org/obo/NCIT_C74270 https://en.wikipedia.org/wiki/Histrelin https://www.wikidata.org/wiki/Q5871149 A long-acting, synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) with potential anti-tumor activity. Upon administration, histrelin binds to and activates GnRH receptors; prolonged administration results in pituitary GnRH receptor desensitization and inhibition of follicle stimulating hormone (FSH) and luteinizing hormone (LH) secretion, leading to a significant decline in testosterone production in males and may inhibit androgen receptor-positive tumor progression; in cisgender women, prolonged administration results in decreased estradiol production. An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, 1-benzyl-D-histidyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the diacetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty. gonadotropin-releasing hormone analog